Guidelines of the IBD working group of the Slovak Society of Gastroenterology on the management of Crohn’s disease

Česká verze

Authors: T. Koller ¹; J. Tóth ¹; T. Hlavatý ¹ ; M. Zakuciová ²; A. Krajčovičová ¹; M. Greguš ³; J. Baláž ⁴; I. Šturdík ¹; M. Huorka ^1*
Authors place of work: Gastroenterologické a hepatologické oddelenie, V. interná klinika LF UK a UN Bratislava ¹; I. interná klinika LF UPJŠ a UN L. Pasteura, Košice ²; Gastroenterologické a hepatologické centrum Nitra, Poliklinika sv. Medarda, Nitra ³; Hepatologicko-gastroenterologicko-transplantačné oddelenie, II. interná klinika SZU a FNsP F. D. Roosevelta, Banská Bystrica ⁴
Published in the journal: Gastroent Hepatol 2018; 72(1): 27-40
Category: IBD: doporučené postupy
doi: https://doi.org/10.14735/amgh201827

*Pracovná skupina pre IBD SGS
Za skupinu členov Pracovnej skupiny pre IBD SGS: M. Bátovský, D. Malík, I. Bunganič, I. Čierna, L. Gombošová, M. Hlísta, M. Horáková, J. Janík, B. Kadlečková, P. Lietava, Ľ. Lukáč, J. Tóth, J. Ušák, B. Valach, I. Valachová, E. Veseliny, A. Vrzgula, J. Záň, Z. Zelinková a autori publikácie

Summary

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for bio medical papers.

Zdroje

1. Bátovský M, Jurgoš Ľ, Bielik J. Racionálna liečba chronických zápalov čreva. Metodický list racionálnej farmakoterapie 2002; 6 (7): 1–4.

2. Greguš M, Huorka M, Lukáč Ľ. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list Ústrednej komisie racionálnej farmakoterapie a liekovej politiky MZ SR 2007; 11 (5–6): 1–8.

3. Kužela L, Zakuciová M. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list racionálnej farmakoterapie a liekovej politiky MZ SR 2012; 15 (5–7): 1–12.

4. Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. Santa Monica: The RAND Corporation 1968.

5. Calvet X, Panés J, Alfaro N et al. Delphi consensus statement: Quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis 2014; 8 (3): 240–251. doi: 10.1016/j.crohns.2013.10.010.

6. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford centre for evidence-based medicine. [online]. Available from: http: //www.cebm.net/index.aspx?o=5653.

7. Howick J, Chalmers I, Glasziou P et al. The 2011 Oxford CEBM Levels of Evidence (Introductory document). Oxford centre for evidence-based medicine. [online]. Available from: http: //www.cebm.net/index.aspx?o=5653.

8. Gomollón F, Dignass A, Annese V et al. 3rd European evidence-based consensus on the diag-nosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017; 11 (1): 3–25. doi: 10.1093/ecco-jcc/jjw168.

9. Rezaie A, Kuenzig ME, Benchimol EI et al. Budesonide for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2015; 6: CD000296. doi: 10.1002/14651858.CD000296.pub4.

10. Moja L, Danese S, Fiorino G et al. Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn‘s disease. Aliment Pharmacol Ther 2015; 41 (11): 1055–1065. doi: 10.1111/apt.13190.

11. Dignass A, Stoynov S, Dorofeyev AE et al. Once versus three times daily dosing of oral budesonide for active Crohn‘s disease: A double-blind, double-dummy, randomised trial. J Crohns Colitis 2014; 8 (9): 970–980. doi: 10.1016/j.crohns.2014.01.021.

12. Tromm A, Bunganič I, Tomsová E et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn‘s disease. Gastroenterology 2011; 140 (2): 425–434. doi: 10.1053/j.gastro.2010.11.004.

13. Lim WC, Wang Y, MacDonald JK et al. Aminosalicylates for induction of remission or response in Crohn‘s disease. Cochrane Database Syst Rev 2016; 7: CD008870. doi: 10.1002/14651858.CD008870.pub2.

14. Benchimol EI, Seow CH, Steinhart AH et al. Traditional corticosteroids for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2008; 2: CD006792. doi: 10.1002/14651858.CD006792.pub2.

15. Gisbert JP, Niño P, Cara C et al. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long‐term, follow‐up study of 394 patients. Aliment Pharmacol Ther 2008; 28 (2): 228–238. doi: 10.1111/j.1365-2036.2008.03732.x

16. Chande N, Tsoulis DJ, MacDonald JK et al. Azathioprine or 6‐mercaptopurine for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2013; 4: CD000545. doi: 10.1002/14651858.CD000545.pub4.

17. Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn‘s disease: results from the CHARM study. Gastroenterology 2008; 135 (5): 1493–1499. doi: 10.1053/j.gastro.2008.07.069.

18. Lichtenstein GR, Yan S, Bala M et al. Remission in patients with Crohn‘s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99 (1): 91–96.

19. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147 (3): 618–627. doi: 10.1053/j.gastro.2014.05.008.

20. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Eng J Med 2016; 375 (20): 1946–1960.

21. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn‘s dis-ease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541–1549.

22. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn‘s disease. N Eng J Med 2004; 350 (9): 876–885.

23. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232–1239. doi: 10.1136/gut.2006.106781.

24. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology 2006; 130 (2): 323–333.

25. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease. N Eng J Med 2013; 369 (8): 711–721. doi: 10.1056/NEJMoa1215739.

26. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn‘s disease. N Eng J Med 2012; 367 (16): 1519–1528. doi: 10.1056/ NEJMoa1203572.

27. Akobeng AK, Zachos M. Tumor necrosis factor‐alpha antibody for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2004; 1: CD003574.

28. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Eng J Med 2010; 362 (15): 1383–1395. doi: 10.1056/NEJMoa0904492.

29. Gecse KB, Lovász BD, Farkas K et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016; 10 (2): 133–140. doi: 10.1093/ecco-jcc/jjv220.

30. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximaba randomized trial. Ann Intern Med 2007; 146 (12): 829–838.

31. Amiot A, Grimaud JC, Peyrin-Biroulet L et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14 (11): 1593–1601. doi: 10.1016/j.cgh.2016.02.016.

32. Baumgart DC, Bokemeyer B, Drabik A et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43 (10): 1090–1102. doi: 10.1111/apt.13594.

33. Osterman MT, Haynes K, Delzell E et al. Comparative effectiveness of infliximab and adalimumab for Crohn‘s disease. Clin Gastroenterol Hepatol 2014; 12 (5): 811–817. doi: 10.1016/j.cgh.2013.06.010.

34. Prantera C, Lochs H, Grimaldi M et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn‘s disease. Gastroenterology 2012; 142 (3): 473–481. doi: 10.1053/j.gastro.2011.11.032.

35. Cosnes J, Bourrier A, Nion-Larmurier I et al. Factors affecting outcomes in Crohn‘s disease over 15 years. Gut 2012; 61 (8): 1140–1145. doi: 10.1136/gutjnl-2011-301971.

36. Akobeng AK, Gardener E. Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn‘s disease. Cochrane Database Syst Rev 2005; 1: CD003715.

37. Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33 (8): 870–879. doi: 10.1111/j.1365-2036.2011.04599.x.

38. Chande N, Patton PH, Tsoulis DJ et al. Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn‘s disease. Cochrane Database Syst Rev 2015; 10: CD000067. doi: 10.1002/14651858.CD000067.pub3.

39. McDonald JW, Tsoulis DJ, Macdonald JK. Methotrexate for induction of remission in refractory Crohn‘s disease. Cochrane Database Syst Rev 2012; 12: CD003459. doi: 10.1002/ 14651858.CD003459.pub3.

40. Patel V, Macdonald JK, McDonald JW et al. Methotrexate for maintenance of remission in Crohn‘s disease. Cochrane Database Syst Rev 2009; 4: CD006884. doi: 10.1002/14651858.CD006884.pub2.

41. Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab maintains remission of Crohn‘s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013; 38 (10): 1236–1247. doi: 10.1111/apt.12499.

42. Sands BE, Sandborn WJ, Van Assche G et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis 2017; 23 (1): 97–106. doi: 10.1097/MIB.0000000000000979.

43. Kennedy NA, Kalla R, Warner B et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014; 40 (11–12): 1313–1323. doi: 10.1111/apt.12980.

44. Torres J, Boyapati RK, Kennedy NA et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015; 149 (7): 1716–1730. doi: 10.1053/j.gastro.2015.08.055.

45. Kennedy NA, Warner B, Johnston EL et al. Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis. Aliment Pharmacol Ther 2016; 43 (8): 910–923. doi: 10.1111/apt.13547.

46. Maire F. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease. Hepato-gastro 2017; 24 (2): 193–199. doi: 10.1684/hpg.2017.1402.

47. Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn‘s disease. Gastroenterology 1990; 99 (4): 956–963.

48. Gionchetti P, Dignass A, Danese S et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 2016; 11 (2): 135–149. doi: 10.1093/ecco-jcc/jjw169.

49. De Cruz P, Kamm MA, Hamilton AL et al. Crohn‘s disease management after intestinal resection: a randomised trial. Lancet 2015; 385 (9976): 1406–1417. doi: 10.1016/S0140-6736 (14) 61908-5.

50. Doherty G, Bennett G, Patil S et al. Interventions for prevention of post‐operative recurrence of Crohn‘s disease. Cochrane Database Syst Rev 2009; 4: CD006873. doi: 10.1002/14651858.CD006873.pub2.

51. Gordon M, Taylor K, Akobeng AK et al, Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn‘s disease. Cochrane Database Syst Rev 2014; 8: CD010233. doi: 10.1002/14651858.CD010233.pub2.

52. Singh S, Garg SK, Pardi DS et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology 2015; 148 (1): 64–76. doi: 10.1053/j.gastro.2014.09.031.

53. Schwartz DA, Loftus EV Jr, Tremaine WJ et al. The natural history of fistulizing Crohn‘s disease in Olmsted County, Minnesota. Gastroenterology 2002; 122 (4): 875–880.

54. Bortlík M. Současný pohled na léčbu perianálních píštělí u nemocných s crohnovou chorobou. Gastroent Hepatol 2013; 67 (1): 25–29.

55. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn‘s disease: current management. J Crohns Colitis 2010; 4 (1): 28–62. doi: 10.1016/j.crohns.2009.12.002.

56. Gecse KB, Bemelman W, Kamm MA et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of peri-anal fistulising Crohn‘s disease. Gut 2014; 63 (9): 1381–1392. doi: 10.1136/gutjnl-2013-306709.

57. Schwartz DA, Ghazi LJ, Regueiro M. Guidelines for medical treatment of crohn‘s perianal fistulas: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2015; 21 (4): 737–752. doi: 10.1097/MIB.0000000000000377.

58. Ong EM, Ghazi LJ, Schwartz DA et al. Guidelines for imaging of Crohn‘s perianal fistulizing disease. Inflamm Bowel Dis 2015; 21 (4): 731–736. doi: 10.1097/MIB.0000000000000367.

59. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula‐in‐ano. Br J Surg 1976; 63 (1): 1–12.

60. Sandborn WJ, Fazio VW, Feagan BG et al. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125 (5): 1508–1530.

61. Keshaw H, Foong K, Forbes A et al. Perianal fistulae in Crohn‘s disease: current and future approaches to treatment. Inflamm Bowel Dis 2010; 16 (5): 870–880. doi: 10.1002/ibd.21137.

62. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn‘s disease. N Eng J Med 1999; 340 (18): 1398–1405.

63. Sands BE, Blank MA, Patel K et al. Long-term treatment of rectovaginal fistulas in Crohn‘s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2 (10): 912–920. doi: 10.1016/S1542-3565 (04) 00414-8.

64. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146 (12): 829–838.

65. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52–65.

66. Hyder SA, Travis SP, Jewell DP et al. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49 (12): 1837–1841.

67. Tanaka S, Matsuo K, Sasaki T et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn‘s disease: when and how were the seton drains removed? Hepatogastroenterology 2010; 57 (97): 3–7.

68. Yassin NA, Askari A, Warusavitarne J et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn‘s disease. Aliment Pharmacol Ther 2014; 40 (7): 741–749. doi: 10.1111/apt.12906.

69. Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 2015; 9 (4): 356–366. doi: 10.1093/ecco-jcc/jjv033.

70. Schwartz DA, Ghazi LJ, Regueiro M et al. Guidelines for the multidisciplinary management of Crohn‘s perianal fistulas: summary statement. Inflamm Bowel Dis 2015; 21 (4): 723–730. doi: 10.1097/MIB.0000000000000315.

71. Bell SJ, Williams AB, Wiesel P et al. The clinical course of fistulating Crohn‘s disease. Aliment Pharmacol Ther 2003; 17 (9): 1145–1151.

72. Baumgart DC, Sandborn WJ. Crohn‘s disease. Lancet 2012; 380 (9853): 1590–1605. doi: 10.1016/S0140-6736 (12) 60026-9.

73. Louis E, Michel V, Hugot JP et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52 (4): 552–557.

74. Rieder F, Zimmermann EM, Remzi FH et al. Crohn‘s disease complicated by strictures: a systematic review. Gut 2013; 62 (7): 1072–1084. doi: 10.1136/gutjnl-2012-304353.

75. Wibmer AG, Kroesen AJ, Gröne J et al. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease – review of the literature. Int J Colorectal Dis 2010; 25 (10): 1149–1157. doi: 10.1007/s00384-010-1010-x.

76. de’Angelis N, Carra MC, Borrelli O et al. Short-and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures. World J Gastroenterol 2013; 19 (17): 2660–2667. doi: 10.3748/wjg.v19.i17.2660.

77. Hassan C, Zullo A, De Francesco V et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther 2007; 26 (11–12): 1457–1464.

78. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn‘s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6 (1): 8–15.

79. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5A–36A.

80. Gasche C, Moser G, Turetschek K et al. Transabdominal bowel sonography for the detection of intestinal complications in Crohn’s disease. Gut 1999; 44 (1): 112–117.

81. Fiorino G, Bonifacio C, Peyrin-Biroulet L et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn‘s disease. Inflamm Bowel Dis 2011; 17 (5): 1073–1080. doi: 10.1002/ibd.21533.

82. Voderholzer WA, Beinhoelzl J, Rogalla P et al. Small bowel involvement in Crohn’s disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut 2005; 54 (3): 369–373.

83. Lang G, Schmiegel W, Nicolas V et al. Impact of small bowel MRI in routine clinical practice on staging of Crohn‘s disease. J Crohns Colitis 2015; 9 (9): 784–794. doi: 10.1093/ecco-jcc/jjv106.

84. Ochsenkühn T, Herrmann K, Schoenberg SO et al. Crohn disease of the small bowel proximal to the terminal ileum: detection by MR‐enteroclysis. Scan J Gastroenterol 2004; 39 (10): 953–960.

85. Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn‘s disease. J Clin Gastroenterol 1983; 5 (3): 211–215.

86. Vasilopoulos S, Kugathasan S, Saeian K et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn‘s disease. Am J Gastroenterol 2000; 95 (9): 2503.

87. Toy LS, Scherl EJ, Kornbluth A et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn’s disease: a series of a newly described complication. Gastroenterology 2000; 118 (Suppl): A569.

88. Pallotta N, Barberani f, Hassan NA et al. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol 2008; 14 (12): 1885–1890.

89. Lichtenstein GR, Olson A, Travers S et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn‘s disease. Am J Gastroenterol 2006; 101 (5): 1030–1038.

90. Bouhnik Y, Carbonnel F, Laharie D et al. Efficacy of adalimumab in patients with Crohn‘s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018; 67 (1): 53–60. doi: 10.1136/gutjnl-2016-312581.

91. Latella G, Sferra R, Speca S et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD. Eur Rev Med Pharmacol Sci 2013; 17 (10): 1283–1304.

92. Froehlich F, Juillerat P, Pittet V et al. Maintenance of surgically induced remission of Crohn’s disease. Digestion 2007; 76 (2): 130–135. doi: 10.1159/000111027.

93. Matsui T, Ikeda K, Tsuda S et al. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn‘s disease: a prospective long-term study. Diagn Ther Endosc 2000; 6 (2): 67–75.

94. Fukumoto A, Tanaka S, Yamamoto H et al. Diagnosis and treatment of small-bowel stricture by double balloon endoscopy. Gastrointest Endosc 2007; 66 (3): S108–S112.

95. Bettenworth D, Lopez R, Gustavsson A et al. Efficacy, safety and longterm outcome of endoscopic dilation therapy for stricturing Crohn’s disease: A combined analysis of 3252 endoscopic balloon dilation procedures. Gastroenterology 2015; 148: 5239–5240.

96. Scimeca D, Mocciaro F, Cottone M et al. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn‘s disease strictures. Dig Liver Dis 2011; 43 (2): 121–125. doi: 10.1016/j.dld.2010.05.001.

97. Couckuyt H, Gevers AM, Coremans G et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn‘s strictures: a prospective longterm analysis. Gut 1995; 36 (4): 577–580.

98. Hoffmann JC, Heller F, Faiss S et al. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis 2008; 23 (7): 689–696. doi: 10.1007/s00384-008-0461-9.

99. Thienpont C, D‘Hoore A, Vermeire S et al. Long-term outcome of endoscopic dilatation in patients with Crohn’s disease is not affected by disease activity or medical therapy. Gut 2010; 59 (3): 320–324. doi: 10.1136/gut.2009.180182.

100. Solem CA, Harmsen SW, Zinsmeister AR et al. Small intestinal adenocarcinoma in Crohn‘s disease: a case‐control study. Inflamm Bowel Dis 2004; 10 (1): 32–35. doi: 10.1097/ 00054725-200401000-00005.

101. Kornbluth A. Endoscopic management of intestinal strictures in Crohn‘s disease: commentary. Inflamm Bowel Dis 2007; 13 (3): 362–363.

102. East JE, Brooker JC, Rutter MD et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn’s strictures. Clin Gastroenterol Hepatol 2007; 5 (9): 1065–1069. doi: 10.1016/j.cgh.2007.04.013.

103. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn‘s colitis. Inflamm Bowel Dis 2008; 14 (2): 213–216.

104. Sorrentino D, Avellini C, Beltrami CA et al. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease. Int J Colorectal Dis 2006; 21 (3): 276–281.

105. Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn‘s disease: report of nine‐year follow‐up and review of the literature. Inflamm Bowel Dis 2012; 18 (3): 506–512. doi: 10.1002/ibd.21739.

106. Attar A, Maunoury V, Vahedi K et al. Sa-fety and efficacy of extractible self‐expandable metal stents in the treatment of Crohn‘s disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis 2012; 18 (10): 1849–1854. doi: 10.1002/ibd.22844.

107. Branche J, Attar A, Vernier-Massouille G et al. Extractible self-expandable metal stent in the treatment of Crohn’s disease anastomotic strictures. Endoscopy 2012; 44 (S02): E325–E326. doi: 10.1055/s-0032-1309854

108. Rejchrt S, Kopacova M, Brozik J et al. Biodegradable stents for the treatment of benign stenoses of the small and large intestines. Endoscopy 2011; 43 (10): 911–917. doi: 10.1055/s-0030-1256405.

109. Toth E, Nielsen J, Nemeth A et al. Treatment of a benign colorectal anastomotic stricture with a biodegradable stent. Endoscopy 2011; 43 (Suppl 2): E252–E253. doi: 10.1055/s-0030-1256511.

110. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6 (10): 991–1030. doi: 10.1016/j.crohns.2012.09.002.

111. Bemelman WA, Allez M. The surgical intervention: earlier or never? B Best Pract Res Clin Gastroenterol 2014; 28 (3): 497–503. doi: 10.1016/j.bpg.2014.04.013.

112. Malgras B, Pautrat K, Dray X et al. Multidisciplinary management of gastrointestinal fibrotic stenosis in Crohn’s disease. Dig Dis Sci 2015; 60 (5): 1152–1168. doi: 10.1007/s10620-014-3421-y.

113. Eshuis EJ, Stokkers PC, Bemelman WA. Decision-making in ileocecal Crohn’s disease management: surgery versus pharmacotherapy. Expert Rev Gastroenterol Hepatol 2010; 4 (2): 181–189. doi: 10.1586/egh.10.3.

114. van Overstraeten AB, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: A reduced need or delayed verdict? World J Gastroenterol 2012; 18 (29): 3828–3832. doi: 10.3748/wjg.v18.i29.3828.

115. Bobanga ID, Bai S, Swanson MA et al. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn‘s disease. Am J Surg 2014; 208 (4): 591–596. doi: 10.1016/j.amjsurg.2014.06.008.

116. Baudry C, Pariente B2 Lourenço N et al. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn‘s disease: a retrospective study. Dig Liver Dis 2014; 46 (10): 887–892. doi: 10.1016/j.dld.2014.07.005.

117. Aratari A, Papi C, Leandro G et al. Early versus late surgery for ileo‐caecal Crohn’s disease. Aliment Pharmacol Ther 2007; 26 (10): 1303–1312. doi: 10.1111/j.1365-2036.2007.03515.x.

118. Latella G, Cocco A, Angelucci E et al. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis 2009; 41 (4): 269–276. doi: 10.1016/j.dld.2008.09.010.

119. Golovics PA, Lakatos L, Nagy A et al. Is early limited surgery associated with a more benign disease course in Crohn’s disease? World J Gastroenterol 2013; 19 (43): 7701–7710. doi: 10.3748/wjg.v19.i43.7701.

120. Kulungowski AM, Acker SN, Hoffenberg EJ et al. Initial operative treatment of isolated ileal Crohn‘s disease in adolescents. Am J Surg 2015; 210 (1): 141–145. doi: 10.1016/j.amjsurg. 2014.07.009.

121. Campbell L, Ambe R, Weaver J et al. Comparison of conventional and nonconventional strictureplasties in Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum 2012; 55 (6): 714–726. doi: 10.1097/DCR.0b013 e31824f875a.

122. Yamamoto T, Keighley M. Follow up of more than 10 years after strictureplasty for jejunoileal Crohn‘s disease: long-term results and predictive factors for outcome. Colorectal Dis 1999; 1 (2): 101–106. doi: 10.1046/ j.1463-1318.1999.00031.x.

123. Fearnhead N, Chowdhury R, Box B et al. Long‐term follow‐up of strictureplasty for Crohn‘s disease. Br J Surg 2006; 93 (4): 475–482. doi: 10.1002/bjs.5179.

124. Michelassi F, Taschieri A, Tonelli F et al. An international, multicenter, prospective, observational study of the side-to-side isoperistaltic strictureplasty in Crohn’s disease. Dis Colon Rectum 2007; 50 (3): 277–284.

125. Tichansky D, Cagir B, Yoo E et al. Strictureplasty for Crohn‘s disease. Dis Colon Rectum 2000; 43 (7): 911–919.

126. Ambe R, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn’s disease: types, indications, comparisons, and safety. J Gastrointest Surg 2012; 16 (1): 209–217. doi: 10.1007/s11605-011-1651-2.

127. Lovasz BD, Lakatos L, Golovics PA et al. Risk of colorectal cancer in Crohn‘s disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary. J Gastrointestin Liver Dis 2013; 22 (3): 265–268.

128. Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7 (12): 982–1018. doi: 10.1016/j.crohns.2013.09.016.

129. Fumery M, Pineton de Chambrun G, Stefanescu C et al. Detection of dysplasia or cancer in 3.5% of patients with inflammatory bowel disease and colonic strictures. Clin Gastroenterol Hepatol 2015; 13 (10): 1770–1775. doi: 10.1016/j.cgh.2015.04.185.

130. Tilney HS, Constantinides VA, Heriot AG et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a metaanalysis. Surg Endosc 2006; 20 (7): 1036–1044.

131. Lee Y, Fleming FJ, Deeb AP et al. A laparoscopic approach reduces short‐term complications and length of stay following ileocolic resection in Crohn’s disease: an analysis of outcomes from the NSQIP database. Colorectal Dis 2012; 14 (5): 572–577. doi: 10.1111/j.1463-1318.2011.02 756.x.

132. Polle SW, Wind J, Ubbink DT et al. Short-term outcomes after laparoscopic ileocolic resection for Crohn’s disease. Dig Surg 2006; 23 (5–6): 346–357. doi: 10.1159/000097950.

133. Polle SW, Bemelman WA. Surgery insight: minimally invasive surgery for IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (6): 324–335.

134. Dasari BV, McKay D, Gardiner K. Laparoscopic versus open surgery for small bowel Crohn’s disease. Cochrane Database Syst Rev 2011; 1: CD006956. doi: 10.1002/14651858.CD006956.pub2.

135. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn’s disease: a meta-analysis. Dis Colon Rectum 2007; 50 (5): 576–585.

136. Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn’s disease. Surg Endosc 2005; 19 (12): 1549–1555.

137. Patel SV, Patel SV, Ramagopalan SV et al. Laparoscopic surgery for Crohn’s disease: a meta-analysis of perioperative complications and long term outcomes compared with open surgery. BMC surg 2013; 13 (1): 14.

138. Gardenbroek TJ, Verlaan T, Tanis PJ et al. Single-port versus multiport laparoscopic ileocecal resection for Crohn‘s disease. J Crohns Colitis 2013; 7 (10): e443–e448. doi: 10.1016/j.crohns.2013.02.015.

139. Van Assche G, Dignass A, Reinisch W et al. The second European evidence-based consensus on the diagnosis and management of Crohn‘s disease: special situations. J Crohns Colitis 2010; 4 (1): 63–101. doi: 10.1016/j.crohns.2009.09.009.

140. Connelly TM, Messaris E. Predictors of recurrence of Crohn’s disease after ileocolectomy: a review. World J Gastroenterol 2014; 20 (39): 14393–14406. doi: 10.3748/wjg.v20.i39.14393.